版本:
中国

BRIEF-Medicines Co, Alnylam Pharma announce agreement with FDA on phase III clinical program for inclisiran

April 26 Medicines Co

* The medicines company and alnylam pharmaceuticals announce agreement with fda on phase iii clinical program for inclisiran

* Medicines co- nda submission anticipated at or around end of 2019

* Medicines co- company has received final, end-of-phase ii meeting minutes from fda Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐